Two new drugs, Orforglipron and Retatrutide, are set to redefine the obesity treatment landscape with their potential affordability and unprecedented efficacy, Scientific American reports.
Potential Game Changers: Orforglipron, one of the two drugs, is anticipated to be easier to use, produce, and likely cheaper than existing treatments.
Internal-medicine physician Sean Wharton at McMaster University, who co-authored the orforglipron study, says “I see it as a game changer, myself.”
The second drug, Retatrutide offers an unprecedented level of efficacy and can potentially raise the bar for treating obesity. Participants lost an average of 24.2% of their body weight over 11 months of treatment when the highest dose was used in the trial. Comparatively, currently approved drugs result about 15–20% weight loss over a similar time frame.
See Also: Elon Musk Says Most People On Earth Have No Idea About Tesla FSD Cars Can Drive Themselves
The Future of Obesity Treatment: While these drugs represent a significant step forward, experts caution that they are not a cure-all.
“The idea that you could stop the medication and not have the weight regain is a non-biological idea, which doesn't make any sense,” says Wharton.
However, the medicines can be a solution for those seeking relief from obesity.
"Medications are not and will not be the only solution, but they are one revolutionary step forward in countering the epidemic," says obesity-medicine specialist Beverly Tchang at Weill Cornell Medicine in New York City.
Read Next: Bitcoin’s Price Could Skyrocket To $120,000 Fueled By Positive Feedback Loop, Says Analyst
Image via i yunmai on Unsplash
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
